© CIC Edizioni Internazionali
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
514 1. ABSTRACT 2. INTRODUCTION Role of Platelet Serotonin in Innate
[Frontiers In Bioscience, Landmark, 24, 514-526, Jan 1, 2019] Role of platelet serotonin in innate immune cell recruitment Claudia Schoenichen1, Christoph Bode1, Daniel Duerschmied1 1Department of Cardiology and Angiology I, Faculty of Medicine, Heart Center, University of Freiburg. Breisacher Str. 33, 79106 Freiburg TABLE OF CONTENTS 1. Abstract 2. Introduction 3. Serotonin and the innate immune system: immune cell recruitment 3.1. Platelets release and respond to serotonin 3.2. Monocytes and macrophages respond to 5-HT in a complex manner 3.3. Serotonin acts as a chemoattractant on dendritic cells 3.4. Serotonin promotes neutrophil recruitment in acute inflammation 3.5. Eosinophil trafficking is enhanced by serotonin 3.6. Basophils/Mast Cells 4. Serotonin and the recruitment of adaptive immune cells 4.1. T lymphocytes 4.2. B lymphocytes 4.3. NK Cells 5. Serotonin on endothelial and smooth muscle cells 6. Conclusion 1. ABSTRACT Serotonin (5-Hydroxytryptamine, 5-HT) was understand the effect of serotonin on immune cell discovered as a vasoconstrictor in 1937. Since its recruitment to sites of inflammation. discovery, the involvement of serotonin in numerous physiological processes was described. It acts as 2. INTRODUCTION an important neurotransmitter, regulates bowel movement, can be released as a tissue hormone Serotonin, 5-Hydroxytryptamine (5-HT), and acts as a growth factor. Among the years, was first discovered by Vittorio Erspamer in 1937. a link between serotonin and inflammation has The Italian pharmacologist extracted an unknown been identified and further evidence suggests an bioactive substance from enterochromaffin gut important role of serotonergic components in immune cells, which showed vasoconstrictive features when responses. -
Would D(+)Adrenaline Have a Therapeutic Effect in Depression
Canadian Open Pharmaceutical, Biological and Chemical Sciences Journal Vol. 1, No. 1, July 2016, pp. 1-6 Available online at http://crpub.com/Journals.php Open Access Research article WOULD D(+)ADRENALINE HAVE A THERAPEUTIC EFFECT IN DEPRESSION José Paulo de Oliveira Filho Projeto Phoenix Avenida Duque de Caxias 1456, 66087-310, Belém, PA [email protected] Mauro Sérgio DorsaCattani Instituto de Física da Universidade de São Paulo C. P. 66318, 05315-970, São Paulo, SP [email protected] José Maria FilardoBassalo Academia Paraense de Ciências Avenida Serzedelo Correa 347/1601,66035-400, Belém, PA [email protected] Nelson Pinheiro Coelho de Souza Escola de Aplicação da UFPA – Belém, PA [email protected] This work is licensed under a Creative Commons Attribution 4.0 International License. _____________________________________________ Abstract In this article, we will analyze a possible therapeutic effect that the enantiomer D (+) of the epinephrine molecule (C9H13NO3) produces in a person who is in a state of depressive anxiety. After presenting a brief historical overview of the depression problem, the discovery of neurotransmitters, the role of enantiomers and the treatment by antidepressants. Just like Citalopram (C20H21N2FO) (Escitalopram), whose antidepressant effect is restricted only to its positive enantiomer [S (+)], we conjecture the existence of an antidepressant effect due to adrenaline also restricted to its positive enantiomer [D (+)].However, up to the moment the production of theD(+)– adrenaline in human body has not been detected yet. We conjecture that the presence of this enantiomer in human body is likely to be detected in blood tests done immediately after parachute jumps. We propose that the D(+) Adrenalineproduction during parachute jumps be caused by the violent emotional shock due to the confrontation with death and that this production happens through the following processes: (a) Almost all L (-) adrenaline becomes D (+) adrenaline through anultra-fast racemization (b) the body itself begins to produce a D(+) adrenaline at large amount. -
The Human Brain Project
HBP The Human Brain Project Madrid, June 20th 2013 HBP The Human Brain Project HBP FULL-SCALE HBP Ramp-up HBP Report mid 2013-end 2015 April, 2012 HBP-PS (CSA) (FP7-ICT-2013-FET-F, CP-CSA, Jul-Oct, 2012 May, 2011 HBP-PS Proposal (FP7-ICT-2011-FET-F) December, 2010 Proposal Preparation August, 2010 HBP PROJECT FICHE: PROJECT TITLE: HUMAN BRAIN PROJECT COORDINATOR: EPFL (Switzerland) COUNTRIES: 23 (EU MS, Switzerland, US, Japan, China); 22 in Ramp Up Phase. RESEARCH LABORATORIES: 256 in Whole Flagship; 110 in Ramp Up Phase RESEARCH INSTITUTIONS (Partners): • 150 in Whole Flagship • 82 in Ramp Up Phase & New partners through Competitive Call Scheme (15,5% of budget) • 200 partners expected by Y5 (Project participants & New partners through Competitive Call Scheme) DIVISIONS:11 SUBPROJECTS: 13 TOTAL COSTS: 1.000* M€; 72,7 M€ in Ramp Up Phase * 1160 M€ Project Total Costs (October, 2012) HBP Main Scheme of The Human Brain Project: HBP Phases 2013 2015 2016 2020 2023 RAMP UP (A) FULLY OPERATIONAL (B) SUSTAINED OPERATIONS (C) Y1 Y2 Y3a Y3b Y4 Y5 Y6 Y7 Y8 Y9 Y10 2014 2020 HBP Structure HBP: 11 DIVISIONS; 13 SUBPROJECTS (10 SCIENTIFIC & APPLICATIONS & ETHICS & MGT) DIVISION SPN1 SUBPROJECTS AREA OF ACTIVITY MOLECULAR & CELLULAR NEUROSCIENCE SP1 STRATEGIC MOUSE BRAIN DATA SP2 STRATEGIC HUMAN BRAIN DATA DATA COGNITIVE NEUROSCIENCE SP3 BRAIN FUNCTION THEORETICAL NEUROSCIENCE SP4 THEORETICAL NEUROSCIENCE THEORY NEUROINFORMATICS SP5 THE NEUROINFORMATICS PLATFORM BRAIN SIMULATION SP6 BRAIN SIMULATION PLATFORM HIGH PERFORMANCE COMPUTING (HPC) SP7 HPC -
Peptide Chemistry up to Its Present State
Appendix In this Appendix biographical sketches are compiled of many scientists who have made notable contributions to the development of peptide chemistry up to its present state. We have tried to consider names mainly connected with important events during the earlier periods of peptide history, but could not include all authors mentioned in the text of this book. This is particularly true for the more recent decades when the number of peptide chemists and biologists increased to such an extent that their enumeration would have gone beyond the scope of this Appendix. 250 Appendix Plate 8. Emil Abderhalden (1877-1950), Photo Plate 9. S. Akabori Leopoldina, Halle J Plate 10. Ernst Bayer Plate 11. Karel Blaha (1926-1988) Appendix 251 Plate 12. Max Brenner Plate 13. Hans Brockmann (1903-1988) Plate 14. Victor Bruckner (1900- 1980) Plate 15. Pehr V. Edman (1916- 1977) 252 Appendix Plate 16. Lyman C. Craig (1906-1974) Plate 17. Vittorio Erspamer Plate 18. Joseph S. Fruton, Biochemist and Historian Appendix 253 Plate 19. Rolf Geiger (1923-1988) Plate 20. Wolfgang Konig Plate 21. Dorothy Hodgkins Plate. 22. Franz Hofmeister (1850-1922), (Fischer, biograph. Lexikon) 254 Appendix Plate 23. The picture shows the late Professor 1.E. Jorpes (r.j and Professor V. Mutt during their favorite pastime in the archipelago on the Baltic near Stockholm Plate 24. Ephraim Katchalski (Katzir) Plate 25. Abraham Patchornik Appendix 255 Plate 26. P.G. Katsoyannis Plate 27. George W. Kenner (1922-1978) Plate 28. Edger Lederer (1908- 1988) Plate 29. Hennann Leuchs (1879-1945) 256 Appendix Plate 30. Choh Hao Li (1913-1987) Plate 31. -
Classification of Single Normal and Alzheimer's Disease Individuals
ORIGINAL RESEARCH published: 23 February 2016 doi: 10.3389/fnins.2016.00047 Classification of Single Normal and Alzheimer’s Disease Individuals from Cortical Sources of Resting State EEG Rhythms Claudio Babiloni 1, 2*, Antonio I. Triggiani 3, Roberta Lizio 1, 2, Susanna Cordone 1, Giacomo Tattoli 4, Vitoantonio Bevilacqua 4, Andrea Soricelli 5, 6, Raffaele Ferri 7, Flavio Nobili 8, Loreto Gesualdo 9, José C. Millán-Calenti 10, Ana Buján 10, Rosanna Tortelli 11, Valentina Cardinali 11, 12, Maria Rosaria Barulli 13, Antonio Giannini 14, Pantaleo Spagnolo 15, Silvia Armenise 16, Grazia Buenza 11, Gaetano Scianatico 13, Giancarlo Logroscino 13, 16, Giovanni B. Frisoni 17, 18 and Claudio del Percio 5 1 Department of Physiology and Pharmacology “Vittorio Erspamer”, University of Rome “La Sapienza”, Rome, Italy, 2 Department of Neuroscience, IRCCS San Raffaele Pisana, Rome, Italy, 3 Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, 4 Department of Electrical and Information Engineering, Polytechnic of Bari, Bari, Italy, 5 Department of Integrated Imaging, IRCCS SDN - Istituto di Ricerca Diagnostica e Nucleare, Napoli, Italy, 6 Department of Edited by: Motor Sciences and Healthiness, University of Naples Parthenope, Naples, Italy, 7 Department of Neurology, IRCCS Oasi Fernando Maestú, Institute for Research on Mental Retardation and Brain Aging, Troina, Italy, 8 Service of Clinical Neurophysiology (DiNOGMI; Complutense University, Spain DipTeC), IRCCS Azienda Ospedaliera Universitaria San Martino - IST, Genoa, Italy, 9 Dipartimento Emergenza e Trapianti d’Organi, University of Bari, Bari, Italy, 10 Gerontology Research Group, Department of Medicine, Faculty of Health Sciences, Reviewed by: University of A Coruña, A Coruña, Spain, 11 Department of Clinical Research in Neurology, University of Bari “Aldo Moro”, Pia José A. -
(PROK2) in Alzheimer's Disease
cells Communication Involvement of the Chemokine Prokineticin-2 (PROK2) in Alzheimer’s Disease: From Animal Models to the Human Pathology Roberta Lattanzi 1, Daniela Maftei 1, Carla Petrella 2, Massimo Pieri 3, Giulia Sancesario 4, Tommaso Schirinzi 5, Sergio Bernardini 3, Christian Barbato 2 , Massimo Ralli 6 , Antonio Greco 6, Roberta Possenti 5, Giuseppe Sancesario 5 and Cinzia Severini 2,* 1 Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University of Rome, P.za A. Moro 5, 00185 Rome, Italy; [email protected] (R.L.); [email protected] (D.M.) 2 Institute of Biochemistry and Cell Biology, IBBC, CNR, Viale del Policlinico, 155, 00161 Rome, Italy; [email protected] (C.P.); [email protected] (C.B.) 3 Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 00133 Rome, Italy; [email protected] (M.P.); [email protected] (S.B.) 4 Neuroimmunology Unit, IRCCS Santa Lucia Foundation, v. Ardeatina 354, 00179 Rome, Italy; [email protected] 5 Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; [email protected] (T.S.); [email protected] (R.P.); [email protected] (G.S.) 6 Department of Sense Organs, University Sapienza of Rome, Viale del Policlinico 155, 00161 Rome, Italy; [email protected] (M.R.); [email protected] (A.G.) * Correspondence: [email protected]; Tel.: +39-06-4997-6742 Received: 17 October 2019; Accepted: 12 November 2019; Published: 13 November 2019 Abstract: Among mediators of inflammation, chemokines play a pivotal role in the neuroinflammatory process related to Alzheimer’s disease (AD). -
Editorial Oxidative Stress As a Pharmacological Target for Medicinal Chemistry: Synthesis and Evaluation of Compounds with Redox Activity - Part 3
414 Current Topics in Medicinal Chemistry, 2015, Vol. 15, No. 5 Editorial Editorial Oxidative Stress as a Pharmacological Target for Medicinal Chemistry: Synthesis and Evaluation of Compounds with Redox Activity - Part 3 Over the last years it has been recognized that a diversity of exogenous and endogenous sources can induce oxidative stress and that free radicals overproduction can cause oxida- tive damage to biomolecules. These events have been linked to several diseases, such as atherosclerosis and other cardiovascular dysfunctions, cancer, diabetics, rheumatoid arthri- tis, chronic inflammation, stroke, aging and neurodegenerative disorders. In oxidative-stress related diseases the endogenous antioxidant defenses have been found to be insufficient to prevent the oxidative damage and as consequence different efforts are currently be under- taken to increase the levels of antioxidants as they can minimize the injury caused by oxida- tive stress. Therefore, the increment of the pool of endogenous antioxidants or the intake of exogenous antioxidants can be an effective therapeutic solution. In this special issue the progresses towards the understanding of the mechanisms of oxi- dative damage and of natural or synthetic antioxidants (lipoic acid and a diversity of pheno- lic systems, namely those based on coumarin and chromone scaffolds) and their interaction with the redox-sensitive signaling pathways involved in the pathophysiology of oxidative- stress related diseases (cancer and neurodegenerative events) are reported. Furthermore the -
Occurrence of Indolealkylamines in Nature by VITTORIO ERSPAMER with One Figure I
Chapter 4 Occurrence of indolealkylamines in nature By VITTORIO ERSPAMER With one Figure I. Introduction Quantitative data on the occurrence of 5-HT and related indolealkylamines in nature are presented in Tables 1-23 of this chapter and in Tables 1-6 of chapter 13. The interest of these data is obvious, especially for the interpretation of the physiological significance of indolealkylamines in their different localizations. However, it seems opportune to call attention at once to a few points. The occurrence of 5-HT or another indolealkylamine in a tissue does not of necessity imply that the amine has particular importance in this tissue. In fact, it is obvious that one is authorized to surmise that a given localization of an indole alkylamine has a general biological significance only if this localization occurs in all or in a great number of species. Quantitative data on the concentration of indolealkylamines in a tissue reflect only a static situation, and they give no indication of the rapidity of synthesis and metabolism of the amines. There is no doubt that knowledge of the turnover rate of the amines in a tissue is considerably more important, from every point of view, than knowledge of the content of the amines at a given moment. To give only one example, it is probable that the amount of 5-HT synthetized and destroyed in a 24-hour period in the rat brain is considerably larger than that metabolized in the skin of Bombina variegata pachy'fYUS or Discoglossus pictus. Yet, it will be seen that the first tissue contains as little as 0.4-0.6 f-lg/g 5-HT, the second 200--450 f-lg/g. -
Recurrence Quantification Analysis of Heart Rate Variability Is a COVID
bioRxiv preprint doi: https://doi.org/10.1101/2021.03.22.436405; this version posted March 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 To Plos One 2 Recurrence quantification analysis of heart rate variability is 3 a COVID-safe alternative to gas analysis in the detection of 4 metabolic thresholds. 5 6 7 G. Zimatore 1,2, L. Falcioni3, M.C. Gallotta4, V. Bonavolontà5, M. Campanella1, M. De Spirito6, L. 8 Guidetti7, C.Baldari1 9 (1) Department of Theoretical and Applied Sciences, eCampus University, Novedrate (CO), 22060, Italy, 10 (2) IMM-CNR, Bologna, Italy 11 (3) Department of Movement, Human and Health Sciences, University of Rome “Foro Italico”, Rome, 12 Italy 13 (4) Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, 14 Italy 15 (5) Department of Basic Medical Sciences, Neuroscience and Sense Organs, University “Aldo Moro”, 16 Bari, Italy Department of Movement, Human and Health Sciences, University of Rome Foro Italico, 17 Rome, Italy 18 (6) Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore Rome, 19 00168, Italy 20 (7) Niccolò Cusano University, Rome, Italy 21 22 23 Key words: phase transition, RQA, aerobic threshold, anaerobic threshold, exercise prescription, 24 determinism, non-linear method 25 26 27 28 29 30 31 32 33 34 35 36 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.03.22.436405; this version posted March 22, 2021. -
Human Brain Project: Henry Markram Plans to Spend €1Bn Building a Perfect Model of the Human Brain | Science | the Observer 08/11/13 14:39
Human Brain Project: Henry Markram plans to spend €1bn building a perfect model of the human brain | Science | The Observer 08/11/13 14:39 Human Brain Project: Henry Markram plans to spend €1bn building a perfect model of the human brain Henry Markram, co-director of the Human Brain Project, based in Lausanne, Switzerland, has been awarded €1bn by the EU. Photograph: Jean-Christophe Bott/EPA In a spartan office looking across Lake Geneva to the French Alps, Henry Markram is searching for a suitably big metaphor to describe his latest project. "It's going to be the Higgs boson of the brain, a Noah's archive of the mind," he says. "No, it's like a telescope that can span all the way across the universe of the brain from the micro the macro level." We are talking about the Human Brain Project, Markram's audacious plan to build a working model of the human brain – from neuron to hemisphere level – and simulate it on a supercomputer within the next 10 years. When Markram first unveiled his idea at a TEDGlobal conference in Oxford four years ago, few of his peers took him seriously. The brain was too complex, they said, and in any case there was no computer fast enough. Even last year when he presented a more detailed plan at a scientific meeting in Bern, showing how the requisite computer power would be available by 2020, many neuroscientists continued to insist it could not be done and dismissed his http://www.theguardian.com/science/2013/oct/15/human-brain-project-henry-markram Pagina 1 di 13 Human Brain Project: Henry Markram plans to spend €1bn building a perfect model of the human brain | Science | The Observer 08/11/13 14:39 claims as hype. -
Chemico-Biological Interactions the Food Contaminant Semicarbazide
Chemico-Biological Interactions 183 (2010) 40–48 Contents lists available at ScienceDirect Chemico-Biological Interactions journal homepage: www.elsevier.com/locate/chembioint The food contaminant semicarbazide acts as an endocrine disrupter: Evidence from an integrated in vivo/in vitro approach Francesca Maranghi a,∗, Roberta Tassinari a, Daniele Marcoccia a, Ilaria Altieri a, Tiziana Catone b, Giovanna De Angelis b, Emanuela Testai b, Sabina Mastrangelo c, Maria Grazia Evandri c, Paola Bolle c, Stefano Lorenzetti a a Department of Food Safety and Veterinary Public Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy b Department of Environment and Primary Prevention, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy c Department of Physiology and Pharmacology “Vittorio Erspamer” Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy article info abstract Article history: Semicarbazide (SEM) is a by-product of the blowing agent azodicarbonamide, present in glass jar-sealed Received 3 August 2009 foodstuffs mainly baby foods. The pleiotropic in vivo SEM toxicological effects suggested to explore its Received in revised form possible role as endocrine modulator. Endocrine effects of SEM were assessed in vivo in male and female 18 September 2009 rats after oral administration for 28 days at 0, 40, 75, 140 mg/kg bw pro die during the juvenile period. Accepted 21 September 2009 Vaginal opening and preputial separation were recorded. Concentration of sex steroid in blood, the ex Available online 27 September 2009 vivo hepatic aromatase activity and testosterone catabolism were detected. The in vitro approach to test SEM role as (anti)estrogen or N-methyl-d-aspartate receptors (NMDARs)-(anti)agonist included dif- Keywords: Semicarbazide ferent assays: yeast estrogenicity, MCF-7 proliferation, stimulation of the alkaline phosphatase activity Food contaminant in Ishikawa cells and LNCaP-based NMDAR interference assay. -
PDF, WIPO Forum 2013 Brochure
WIPO Forum 2013 From inspiration to innovation: The game-changers September 24, 2013 – 3.30 p.m. International Conference Center Geneva (CICG) Geneva, Switzerland WIPO Forum 2013 What would you change to ensure that future generations see widespread improvements in nutrition, in shelter, and in new therapies to heal troubled minds and bodies? Important breakthroughs are already while opening up the possibility of new on our doorstep and the WIPO Forum markets and new solutions—including 2013 is bringing together four vision- some that may still lie beyond the limits ary innovators, each disrupting cur- of our imagination. rent paradigms in a quest to improve some of the most basic elements of the For forward-looking policy makers, human experience: food, shelter, and here’s the question: How do we foster health. Their individual achievements a creative environment that promotes are astonishing. the kind of ground-breaking work done by the WIPO Forum 2013 panelists, That they share so much in com- while ensuring that the improvements mon is no less surprising. The work lift up our entire communities? What do of each of these change-makers has the innovators of the future need from challenged long-established industrial us—now? The first step in finding the styles, methods or modes of thought, answer is asking the question. Please join us for an interactive session on September 24 at the WIPO Forum 2013 on From inspiration to innovation: The game- changers and hear our panelists’ stories. 2 From inspiration to innovation: The game-changers Anthony Atala. For years, the needs of organ-transplant patients have far out- stripped the number of donors.